{"id":97,"date":"2020-04-21T10:34:00","date_gmt":"2020-04-21T10:34:00","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=97"},"modified":"2020-05-12T05:57:50","modified_gmt":"2020-05-12T05:57:50","slug":"5-april-2020-favipiravir-check-for-ddis-due-to-ao-inhibition","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/5-april-2020-favipiravir-check-for-ddis-due-to-ao-inhibition\/","title":{"rendered":"(5 April 2020) Favipiravir: Check for DDIs due to AO inhibition"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p>Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection.<\/p>\n<p><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/research\/coronavirus\/publication\/32246834\">https:\/\/www.ncbi.nlm.nih.gov\/research\/coronavirus\/publication\/32246834<\/a><\/p>\n<p class=\"\">Favipiravir provides a substitute for compassionate use in COVID-19 based on its mechanism of action inhibiting virus RdRp and safety data in previous clinical studies. Data obtained from influenza treatment and proof-of-concept clinical trial in Ebola Virus Disease aids the determination of dose regimen in clinical trials or experimental use of the drug in COVID-19. However, the exact efficacy of favipiravir awaits further clinical confirmation. Potential drug-drug interactions (DDIs) due to Aldehyde Oxidase (AO) inhibition should not be ignored in the clinical setting.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection. https:\/\/www.ncbi.nlm.nih.gov\/research\/coronavirus\/publication\/32246834 Favipiravir provides a substitute for compassionate use in COVID-19 based on its mechanism of action inhibiting virus RdRp and safety data in previous clinical studies. Data obtained from influenza&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/5-april-2020-favipiravir-check-for-ddis-due-to-ao-inhibition\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(5 April 2020) Favipiravir: Check for DDIs due to AO inhibition&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,11],"tags":[26],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/97"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=97"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/97\/revisions"}],"predecessor-version":[{"id":98,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/97\/revisions\/98"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=97"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=97"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=97"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}